302 related articles for article (PubMed ID: 32747394)
1. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
Ramalho AS; Fürstová E; Vonk AM; Ferrante M; Verfaillie C; Dupont L; Boon M; Proesmans M; Beekman JM; Sarouk I; Vazquez Cordero C; Vermeulen F; De Boeck K;
Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32747394
[TBL] [Abstract][Full Text] [Related]
2. Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast.
Latorre RV; Calicchia M; Bigliardi M; Conti J; Kleinfelder K; Melotti P; Sorio C
Respir Investig; 2024 May; 62(3):455-461. PubMed ID: 38547757
[TBL] [Abstract][Full Text] [Related]
3. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
[TBL] [Abstract][Full Text] [Related]
4. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
Boj SF; Vonk AM; Statia M; Su J; Vries RR; Beekman JM; Clevers H
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287550
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Functional Characteristics of the E92K
Kondratyeva E; Melyanovskaya Y; Bulatenko N; Davydenko K; Filatova A; Efremova A; Skoblov M; Bukharova T; Sherman V; Voronkova A; Zhekaite E; Krasovskiy S; Amelina E; Petrova N; Polyakov A; Adyan T; Starinova M; Krasnova M; Vasilyev A; Makhnach O; Zinchenko R; Kutsev S; Gokdemir Y; Karadag B; Goldshtein D
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047318
[TBL] [Abstract][Full Text] [Related]
6. β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.
Vijftigschild LA; Berkers G; Dekkers JF; Zomer-van Ommen DD; Matthes E; Kruisselbrink E; Vonk A; Hensen CE; Heida-Michel S; Geerdink M; Janssens HM; van de Graaf EA; Bronsveld I; de Winter-de Groot KM; Majoor CJ; Heijerman HG; de Jonge HR; Hanrahan JW; van der Ent CK; Beekman JM
Eur Respir J; 2016 Sep; 48(3):768-79. PubMed ID: 27471203
[TBL] [Abstract][Full Text] [Related]
7. Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.
de Poel E; Spelier S; Suen SWF; Kruisselbrink E; Graeber SY; Mall MA; Weersink EJM; van der Eerden MM; Koppelman GH; van der Ent CK; Beekman JM
J Cyst Fibros; 2022 Mar; 21(2):246-253. PubMed ID: 34666947
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity.
Zomer-van Ommen DD; de Poel E; Kruisselbrink E; Oppelaar H; Vonk AM; Janssens HM; van der Ent CK; Hagemeijer MC; Beekman JM
J Cyst Fibros; 2018 May; 17(3):316-324. PubMed ID: 29544685
[TBL] [Abstract][Full Text] [Related]
9. Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations.
de Winter-de Groot KM; Berkers G; Marck-van der Wilt REP; van der Meer R; Vonk A; Dekkers JF; Geerdink M; Michel S; Kruisselbrink E; Vries R; Clevers H; Vleggaar FP; Elias SG; Heijerman HGM; van der Ent CK; Beekman JM
J Cyst Fibros; 2020 Jul; 19(4):614-619. PubMed ID: 31735562
[TBL] [Abstract][Full Text] [Related]
10. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
12. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.
de Poel E; Spelier S; Hagemeijer MC; van Mourik P; Suen SWF; Vonk AM; Brunsveld JE; Ithakisiou GN; Kruisselbrink E; Oppelaar H; Berkers G; de Winter de Groot KM; Heida-Michel S; Jans SR; van Panhuis H; Bakker M; van der Meer R; Roukema J; Dompeling E; Weersink EJM; Koppelman GH; Blaazer AR; Muijlwijk-Koezen JE; van der Ent CK; Beekman JM
J Cyst Fibros; 2023 May; 22(3):548-559. PubMed ID: 37147251
[TBL] [Abstract][Full Text] [Related]
13. Molecular Dynamics and Theratyping in Airway and Gut Organoids Reveal R352Q-CFTR Conductance Defect.
Wong SL; Awatade NT; Astore MA; Allan KM; Carnell MJ; Slapetova I; Chen PC; Setiadi J; Pandzic E; Fawcett LK; Widger JR; Whan RM; Griffith R; Ooi CY; Kuyucak S; Jaffe A; Waters SA
Am J Respir Cell Mol Biol; 2022 Jul; 67(1):99-111. PubMed ID: 35471184
[TBL] [Abstract][Full Text] [Related]
14. R560S: A class II CFTR mutation that is not rescued by current modulators.
Awatade NT; Ramalho S; Silva IAL; Felício V; Botelho HM; de Poel E; Vonk A; Beekman JM; Farinha CM; Amaral MD
J Cyst Fibros; 2019 Mar; 18(2):182-189. PubMed ID: 30030066
[TBL] [Abstract][Full Text] [Related]
15. CFTR Modulators Rescue the Activity of CFTR in Colonoids Expressing the Complex Allele p.[R74W;V201M;D1270N]/dele22_24.
Kleinfelder K; Somenza E; Farinazzo A; Conti J; Lotti V; Latorre RV; Rodella L; Massella A; Tomba F; Bertini M; Sorio C; Melotti P
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982273
[TBL] [Abstract][Full Text] [Related]
16. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
[TBL] [Abstract][Full Text] [Related]
17. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
18. Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.
Dekkers JF; Van Mourik P; Vonk AM; Kruisselbrink E; Berkers G; de Winter-de Groot KM; Janssens HM; Bronsveld I; van der Ent CK; de Jonge HR; Beekman JM
J Cyst Fibros; 2016 Sep; 15(5):568-78. PubMed ID: 27160424
[TBL] [Abstract][Full Text] [Related]
19. Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype.
Aalbers BL; Brunsveld JE; van der Ent CK; van den Eijnden JC; Beekman JM; Heijerman HGM
J Cyst Fibros; 2022 Mar; 21(2):254-257. PubMed ID: 35110005
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.
Chen KG; Zhong P; Zheng W; Beekman JM
Drug Discov Today; 2019 Nov; 24(11):2126-2138. PubMed ID: 31173911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
